Susquehanna Fundamental Investments LLC Makes New $43.59 Million Investment in Bristol-Myers Squibb (NYSE:BMY)

Susquehanna Fundamental Investments LLC acquired a new position in Bristol-Myers Squibb (NYSE:BMY - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 770,690 shares of the biopharmaceutical company's stock, valued at approximately $43,590,000. Bristol-Myers Squibb makes up 0.6% of Susquehanna Fundamental Investments LLC's investment portfolio, making the stock its 7th biggest position.

Several other institutional investors also recently modified their holdings of the business. Morse Asset Management Inc increased its stake in Bristol-Myers Squibb by 25.0% during the 3rd quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock valued at $517,000 after purchasing an additional 2,000 shares in the last quarter. Tudor Financial Inc. bought a new stake in Bristol-Myers Squibb during the 3rd quarter valued at about $250,000. Pine Valley Investments Ltd Liability Co increased its stake in Bristol-Myers Squibb by 1.3% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company's stock valued at $2,323,000 after purchasing an additional 575 shares in the last quarter. World Investment Advisors LLC increased its stake in Bristol-Myers Squibb by 18.7% during the 3rd quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock valued at $2,282,000 after purchasing an additional 6,954 shares in the last quarter. Finally, Arvest Bank Trust Division bought a new stake in Bristol-Myers Squibb during the 3rd quarter valued at about $1,724,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock traded down $0.47 during trading on Thursday, reaching $49.73. 7,686,018 shares of the stock traded hands, compared to its average volume of 12,939,105. The company has a market capitalization of $101.21 billion, a price-to-earnings ratio of -11.24, a P/E/G ratio of 2.07 and a beta of 0.41. The business has a fifty day simple moving average of $55.99 and a two-hundred day simple moving average of $56.41. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the business posted ($4.40) earnings per share. The business's quarterly revenue was down 5.6% compared to the same quarter last year. Sell-side analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.99%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb's payout ratio is 92.88%.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Finally, Truist Financial raised their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $58.00.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average price of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.